Skip to content

Incidence of postoperative residual curarization in the post-anaesthesia recovery unit

A study on the incidence and prevalence of postoperative residual curarization (PORC) in the post anaesthetic care unit (PACU) in female patients who underwent a general anaesthetic and received neuromuscular blocking drug (NMBD) for major gynaecological, breast , reconstructive or aesthetic surgery.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12613001357741
Acronym
Incidence of PORC in PACU
Enrollment
250
Registered
2013-12-11
Start date
2013-12-03
Completion date
2014-11-20
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

We aimed to characterize and define the incidence and prevalence of postoperative residual curarization (PORC) in the post anaesthetic care unit (PACU) of our tertiary referral women’s centre in 250 patients after major gynaecological, breast and aesthetic surgery. Our primary outcome variable is the incidence of PORC in awake extubated patients 10 min post-PACU arrival, where a TOF ratio <0.9 is used as criteria for defining postoperative residual weakness. Secondary outcome measures studied are the presence of side effects (nausea and vomiting), adverse respiratory events, time to PACU discharge readiness and actual length of PACU stay.

Interventions

The incidence of PORC in awake extubated patients 10 min post-PACU arrival. (defined as a nerve stimulation Train Of Four ratio <0.9 for postoperative residual weakness.)

Sponsors

Dr Wendy H.L.Teoh
Lead SponsorIndividual

Eligibility

Sex/Gender
All
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

ASA I-III patients who underwent a general anaesthetic for major gynaecological, breast , reconstructive or aesthetic surgery, in whom a neuromuscular blocking drug was administered.

Exclusion criteria

< 21 years, had underlying neuromuscular disease, use of medication known to interfere with neuromuscular transmission.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026